Soligenix (SNGX) Earning Somewhat Positive Press Coverage, Study Finds
News stories about Soligenix (NASDAQ:SNGX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Soligenix earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.927278812837 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Soligenix (SNGX) and ContraFect (CFRX) Head-To-Head Contrast (americanbankingnews.com)
- Soligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA (finance.yahoo.com)
- $1.58 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter (americanbankingnews.com)
- Head-To-Head Survey: Soligenix (SNGX) vs. Mirati Therapeutics (MRTX) (americanbankingnews.com)
SNGX has been the topic of several recent analyst reports. Maxim Group set a $5.00 price objective on Soligenix and gave the company a “buy” rating in a research note on Tuesday, October 24th. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Soligenix in a research note on Thursday, September 21st.
Shares of Soligenix (NASDAQ SNGX) traded down $0.07 during trading hours on Thursday, reaching $2.02. The company’s stock had a trading volume of 60,600 shares, compared to its average volume of 261,003. Soligenix has a fifty-two week low of $1.74 and a fifty-two week high of $5.08.
Soligenix (NASDAQ:SNGX) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.15. Soligenix had a negative return on equity of 112.81% and a negative net margin of 90.93%. The business had revenue of $1.82 million for the quarter, compared to analysts’ expectations of $1.36 million. equities research analysts anticipate that Soligenix will post -1.28 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Soligenix (SNGX) Earning Somewhat Positive Press Coverage, Study Finds” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/soligenix-sngx-earning-somewhat-positive-press-coverage-study-finds/1735764.html.
Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.